Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

A surprising acne rosacea remedy

Martin C. Young, MD
Conditions
November 6, 2023
Share
Tweet
Share

I have typically managed my mild case of acne rosacea (AR) with affordable over-the-counter (OTC) medications, but there has always been a residual redness that bothered me.

Recently, while reading about Demodex, microscopic mites that live on the faces of many of us in our hair follicles and sebaceous glands, I became interested in their potential connection to AR. I wondered if a topical mitocidal treatment might be helpful. Some research confirmed that ivermectin was indeed effective in treating AR.

So, I decided to acquire some.

As a pediatrician, I’m familiar with ivermectin because it’s used to treat head lice, a common childhood complaint. It was once available only by prescription but is now available over the counter as a lotion, priced at around $35.

I delved deeper into my research and soon discovered that AR treatment involved a 1% ivermectin cream, available in both brand and generic versions.

I consulted my Medicare Part D drug list and was shocked by the cost I would have to bear, especially considering that it was only available through a “step therapy” process, which required trying other cheaper medications first. So, I turned to the GoodRx website, which indicated an “average retail price” of $567 but promised that, with their coupon, I could obtain a small tube (45 g, enough for one month) for anywhere between $140 to $280. The Amazon online pharmacy quoted $509 for the brand Soolantra and $379 for the generic version.

Are you kidding me? Could I not find access to this straightforward medication, which has been in medical use since 1987 (and earned its inventor a Nobel Prize)? I scoured Amazon and found numerous options for a veterinary preparation used to deworm horses; a 6 g tube of 1.82% ivermectin was as cheap as $12! I wondered if I could use this topically for my AR.

Further research revealed that this was indeed a common practice among AR sufferers who faced the exorbitant cost of the human topical product. Some articles even included interviews with dermatologists who disapproved of the practice, albeit for safety reasons. One couldn’t help but wonder if they were protecting their interests.

So, I purchased some of the horse paste, which had a pleasant apple scent (and apparently, a taste for horses). Before applying it, I mixed it half and half with some hand cream from the dollar store ($1.25). I can confidently report a noticeable improvement in redness after only a few days. By the two-month mark, my AR had disappeared.

Why then is 1% ivermectin cream, whether brand or generic, so expensive? Clearly, it’s not due to the cost of the ingredients. I’m sure that if a representative of the Soolantra brand were questioned, they would mention expenses related to research, safety trials, and the like. My response would be, “Can you please explain why I can obtain your product through a legitimate government-regulated online pharmacy in the U.K. for about $40?” I’d watch them blush.

It’s hard to escape the conclusion that Big Pharma is once again taking advantage of us Americans.

Martin C. Young is a pediatric endocrinologist.

Prev

Empowering health care professionals through mindfulness [PODCAST]

November 5, 2023 Kevin 0
…
Next

Antisemitism is at a historic high not just in other countries, but right here in America

November 6, 2023 Kevin 7
…

ADVERTISEMENT

Tagged as: Dermatology

Post navigation

< Previous Post
Empowering health care professionals through mindfulness [PODCAST]
Next Post >
Antisemitism is at a historic high not just in other countries, but right here in America

ADVERTISEMENT

More by Martin C. Young, MD

  • Is there a place for audiovisual recording in medicine?

    Martin C. Young, MD
  • My battle with atrial fibrillation

    Martin C. Young, MD
  • What happened to the chemical pathologist?

    Martin C. Young, MD

Related Posts

  • Chlorophyll, acne, and TikTok: Should these mix?

    Casey Paul Schukow and Vanessa Tan
  • 3 surprising links to medical errors

    Health eCareers
  • The surprising impact of medical students on patients

    Nicole Cifra, MD, MPH
  • The evolution of medical training in dermatology and the impact of technology

    Peter Lio, MD
  • How to match into dermatology: A medical student shares her success story

    Jenny Wang
  • More than skin deep: the importance of culturally competent care in medical education

    Grace Shadid

More in Conditions

  • When doctors don’t talk: a silent failure in modern medicine

    Cesar Querimit, Jr.
  • The many faces of physician grief

    Annia Raja, PhD
  • How early care saved my life from silent kidney disease

    Charlie Cloninger
  • Why GLP‑1 drugs should be covered beyond weight loss

    Rodney Lenfant
  • When recurrent UTIs might actually be bladder cancer

    Fara Bellows, MD
  • How chronic stress harms the heart in minority communities

    Monzur Morshed, MD and Kaysan Morshed
  • Most Popular

  • Past Week

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • Could antibiotics beat heart disease where statins failed?

      Larry Kaskel, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • The backbone of health care is breaking

      Grace Yu, MD | Physician
    • Why palliative care is more than just end-of-life support

      Dr. Vishal Parackal | Conditions
    • Why transplant equity requires more than access

      Zamra Amjid, DHSc, MHA | Policy
  • Past 6 Months

    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • COVID-19 was real: a doctor’s frontline account

      Randall S. Fong, MD | Conditions
    • Why primary care doctors are drowning in debt despite saving lives

      John Wei, MD | Physician
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • Why transplant equity requires more than access

      Zamra Amjid, DHSc, MHA | Policy
    • An IMG’s story of exclusion in U.S. residency

      Fereshteh Kagar Bafrani, MD | Physician
    • The 4 foundations that sustain physicians through burnout and balance

      Ananta Subedi, MD, MPH | Physician
    • Should anesthesiologists object to unnecessary procedures?

      Deepak Gupta, MD | Physician
    • Ideology, not evidence, fuels the anti-trans agenda

      Andie Riffer, PhD and Shawn E. Parra, LCSW, MSW | Policy
    • How Ukrainian doctors sustained diabetes care during the war [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • Could antibiotics beat heart disease where statins failed?

      Larry Kaskel, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • The backbone of health care is breaking

      Grace Yu, MD | Physician
    • Why palliative care is more than just end-of-life support

      Dr. Vishal Parackal | Conditions
    • Why transplant equity requires more than access

      Zamra Amjid, DHSc, MHA | Policy
  • Past 6 Months

    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • COVID-19 was real: a doctor’s frontline account

      Randall S. Fong, MD | Conditions
    • Why primary care doctors are drowning in debt despite saving lives

      John Wei, MD | Physician
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • Why transplant equity requires more than access

      Zamra Amjid, DHSc, MHA | Policy
    • An IMG’s story of exclusion in U.S. residency

      Fereshteh Kagar Bafrani, MD | Physician
    • The 4 foundations that sustain physicians through burnout and balance

      Ananta Subedi, MD, MPH | Physician
    • Should anesthesiologists object to unnecessary procedures?

      Deepak Gupta, MD | Physician
    • Ideology, not evidence, fuels the anti-trans agenda

      Andie Riffer, PhD and Shawn E. Parra, LCSW, MSW | Policy
    • How Ukrainian doctors sustained diabetes care during the war [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...